Evolus executive sells over $89k in company stock - Investing.com

Q: Is Evolus a profitable stock?

Full-year revenue guidance was “narrowed” to $260m - $266m — an annual uplift of 29% - 32% — and stated it would be profitable on a non-GAAP basis in Q4 2024, and in full-year 2025, and finally, that it: Despite the generally positive nature of these updates, Evolus stock slipped <$12 per share by the middle of November.

Q: Should you buy Evolus stock after Q3 earnings?

Unfortunately, although Evolus stock enjoyed a strong bull run between June and early November last year, with shares reaching a high of $17 per share, a market cap valuation of roughly just under $1bn, it then began to tumble in value after Evolus released a weak set of Q3 earnings. At first, the results and updates appear quite positive.

Q: Should I buy Evolus?

My “Buy” recommendation was based on several factors. Firstly, the company has settled litigation with AbbVie (ABBV), who market and sell Botox, the leading product in the field, which earned $2.7bn in aesthetics markets, and $3bn as a migraine therapy, in 2023. AbbVie alleged that Evolus stole trade secrets and used them to develop Jeuveau.

Q: Is Evolus launching a second product?

Well, between 2020 and 2023 Evolus nearly quadrupled its revenues, and it is in the process of launching a second product that could be even more lucrative.

Q: Did Evolus steal trade secrets?

AbbVie alleged that Evolus stole trade secrets and used them to develop Jeuveau. However, the litigation was settled, with AbbVie granting Evolus a license to keep selling its product.

Sep 4, 2024 · Additionally, Evolus is trading near its 52-week high, with the price at 95.03% of this peak, which aligns with the strong return over the last year, as indicated by a 57.21% price …

03%
OFF

Evolus Executive Sells Over $89k In Company Stock - Investing.com

1 week from now

Sep 4, 2024 · Additionally, Evolus is trading near its 52-week high, with the price at 95.03% of this peak, which aligns with the strong return over the last year, as indicated by a 57.21% price …

investing.com

$89
OFF

Evolus Executive Sells Over $89k In Company Stock - Investing.com …

1 week from now

Evolus executive sells over $89k in company stock

investing.com

$89
OFF

Evolus Executive Sells Over $89k In Company Stock

1 week from now

Evolus executive sells over $89k in company stock

investing.com

$384
OFF

Evolus Executive Sells Over $384k In Company Stock - Investing.com

1 week from now

Mar 21, 2024 · Evolus, Inc.'s (NASDAQ: EOLS) Chief Medical Officer & Head of Research and Development, Rui Avelar, recently sold 27,603 shares of the company's stock, netting a total …

investing.com

$78
OFF

Evolus CFO Sandra Beaver Sells Over $78k In Company Stock

1 week from now

Mar 21, 2024 · Evolus, Inc. (NASDAQ: EOLS) Chief Financial Officer Sandra Beaver has sold a total of $78,978 worth of company stock, as revealed in a recent filing with the Securities and …

investing.com

$49000
OFF

Evolus CFO Sandra Beaver Sells Shares Worth Over $49,000

1 week from now

Sep 7, 2024 · Evolus, Inc.'s (NASDAQ: EOLS) Chief Financial Officer, Sandra Beaver, recently sold company shares, resulting in a transaction exceeding $49,000.The sale, dated …

investing.com

$200
OFF

Evolus CEO Sells Over $200k In Company Stock - Investing.com UK

1 week from now

May 15, 2024 · Evolus (NASDAQ: EOLS), Inc. CEO David Moatazedi recently completed a stock sale transaction, disposing of a total of 16,051 shares of the company's common stock, …

investing.com

$200
OFF

Evolus CEO Sells Over $200k In Company Stock By Investing.com

1 week from now

May 15, 2024 · Evolus CEO sells over $200k in company stock. English (USA)

investing.com

$24438
OFF

Evolus Chief Medical Officer Sells Shares Worth $24,438

1 week from now

Dec 26, 2024 · NEWPORT BEACH, CA—Evolus, Inc. (NASDAQ: EOLS) Chief Medical (TASE: PMCN) Officer and Head of Research and Development, Rui Avelar, has recently sold 2,252 …

investing.com

$200
OFF

Evolus CEO Sells Over $200k In Company Stock - Investing.com India

1 week from now

Evolus CEO sells over $200k in company stock

investing.com

$200
OFF

Evolus CEO Sells Over $200k In Company Stock - Investing.com

1 week from now

May 14, 2024 · Evolus (NASDAQ: EOLS), Inc. CEO David Moatazedi recently completed a stock sale transaction, disposing of a total of 16,051 shares of the company's common stock, …

investing.com

$30
OFF

Evolus CFO Sandra Beaver Sells Shares Worth Over $30k

1 week from now

May 15, 2024 · Evolus Inc .'s (NASDAQ: EOLS) Chief Financial Officer, Sandra Beaver, has recently sold a portion of her company shares, resulting in a transaction value exceeding …

investing.com

$362
OFF

Evolus Director Vikram Malik Sells $362k In Company Stock

1 week from now

In a recent transaction, Vikram Malik, a director at Evolus, Inc. (NASDAQ:EOLS), sold 28,000 shares of the company's stock, netting a total of $362,012. The shares were sold at prices …

investing.com

$49000
OFF

Evolus CFO Sandra Beaver Sells Shares Worth Over $49,000

1 week from now

Sep 6, 2024 · Evolus, Inc.'s (NASDAQ: EOLS) Chief Financial Officer, Sandra Beaver, recently sold company shares, resulting in a transaction exceeding $49,000. The sale, dated …

investing.com

$362
OFF

Evolus Director Vikram Malik Sells $362k In Company Stock

1 week from now

May 15, 2024 · Read Evolus director Vikram Malik sells $362k in company stock By Investing.com. Evolus director Vikram Malik sells $362k in company stock. Download the App. …

investing.com

$24438
OFF

Evolus Chief Medical Officer Sells Shares Worth $24,438

1 week from now

Dec 26, 2024 · Evolus chief medical officer sells shares worth $24,438 ... Rui Avelar, has recently sold 2,252 shares of the company's common stock. The transaction, which took place on …

investing.com

62%
OFF

Evolus Stock Soars To 52-week High, Hits $17.75 - Investing.com

1 week from now

Oct 14, 2024 · Evolus stock soars to 52-week high, hits $17.75 ... The company's stock has demonstrated a robust 107.62% price total return over the past year, aligning closely with the …

investing.com

$213889
OFF

Ionis Pharmaceuticals EVP Sells $213,889 In Stock - Investing.com

1 week from now

2 hours ago · Bitcoin price today: rises above $102k ahead of Trump’s inauguration By Investing.com - Jan 17, 2025 3 More News 5 Quality Growth Stocks Poised for Strong Returns …

investing.com

FAQs about Evolus executive sells over $89k in company stock - Investing.com Coupon?

What happened to Evolus stock in November?

Despite the generally positive nature of these updates, Evolus stock slipped <$12 per share by the middle of November. It mounted a slight comeback to ~$14 per share, then crashed again in December, and has kept falling to its current price of $9.3 per share. What, then, is turning the market against Evolus and its business? ...

Is Evolus a profitable stock?

Full-year revenue guidance was “narrowed” to $260m - $266m — an annual uplift of 29% - 32% — and stated it would be profitable on a non-GAAP basis in Q4 2024, and in full-year 2025, and finally, that it: Despite the generally positive nature of these updates, Evolus stock slipped <$12 per share by the middle of November. ...

Should you buy Evolus stock after Q3 earnings?

Unfortunately, although Evolus stock enjoyed a strong bull run between June and early November last year, with shares reaching a high of $17 per share, a market cap valuation of roughly just under $1bn, it then began to tumble in value after Evolus released a weak set of Q3 earnings. At first, the results and updates appear quite positive. ...

Should I buy Evolus?

My “Buy” recommendation was based on several factors. Firstly, the company has settled litigation with AbbVie (ABBV), who market and sell Botox, the leading product in the field, which earned $2.7bn in aesthetics markets, and $3bn as a migraine therapy, in 2023. AbbVie alleged that Evolus stole trade secrets and used them to develop Jeuveau. ...

Is Evolus launching a second product?

Well, between 2020 and 2023 Evolus nearly quadrupled its revenues, and it is in the process of launching a second product that could be even more lucrative. ...

Did Evolus steal trade secrets?

AbbVie alleged that Evolus stole trade secrets and used them to develop Jeuveau. However, the litigation was settled, with AbbVie granting Evolus a license to keep selling its product. ...